1. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

   • Daniel N. Cagney
   • Brian M. Alexander
   • Ayal A. Aizer

   Topic Review 11 July 2016 Pages: 389 - 393

   

2. SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis)

   • Chanida Vinayanuwattikun
   • Siyamol Mingmalairak
   • Shanop Shuangshoti

   Laboratory Investigation 11 July 2016 Pages: 395 - 403

   

3. Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role

   • Elia Guadagno
   • Marialaura Del Basso De Caro
   • Flavia Dones

   Laboratory Investigation 09 July 2016 Pages: 405 - 413

   

4. Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors

   • Irena Srebotnik-Kirbiš
   • Clara Limbäck-Stokin

   Laboratory Investigation 12 July 2016 Pages: 415 - 422

   

5. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma

   • Yongxiao Li
   • Tao Jiang
   • Qing Chang

   Laboratory Investigation 12 July 2016 Pages: 423 - 431

   

6. The effects of sequential treatments on hippocampal volumes in malignant glioma patients

   • Shantell C. Nolen
   • Brian Lee
   • Daniela A. Bota

   Clinical Study 08 July 2016 Pages: 433 - 441

   

7. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study

   • Ralph Salloum
   • Trent R. Hummel
   • Rachid Drissi

   Clinical Study 27 June 2016 Pages: 443 - 451

   

8. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

   • Deborah T. Blumenthal
   • Michal Yalon
   • Felix Bokstein

   Clinical Study 04 July 2016 Pages: 453 - 460

   

9. Does the choice of antiepileptic drug affect survival in glioblastoma patients?

   • Kristin M. Knudsen-Baas
   • Anders Engeland
   • Jone F. Owe

   Clinical Study 04 July 2016 Pages: 461 - 469

   

10. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma

    • Arian Lasocki
    • Frank Gaillard
    • Stephen L. Stuckey

    Clinical Study 13 July 2016 Pages: 471 - 478

    

11. Age alone is not a predictor for survival in glioblastoma

    • Lucy Gately
    • Anna Collins
    • Anthony Dowling

    Clinical Study 12 July 2016 Pages: 479 - 485

    

12. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

    • Shiao-Pei Weathers
    • Xiaosi Han
    • John F. de Groot

    Clinical Study 12 July 2016 Pages: 487 - 494

    

13. The clinical significance of fascin expression in a newly diagnosed primary glioblastoma

    • Ki-Su Park
    • Hye Won Lee
    • Jeong-Hyun Hwang

    Clinical Study 12 July 2016 Pages: 495 - 503

    

14. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

    • Tomohiro Kawaguchi
    • Yukihiko Sonoda
    • Teiji Tominaga

    Clinical Study 11 July 2016 Pages: 505 - 514

    

15. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study

    • Magnus Sabel
    • Gudrun Fleischhack
    • On behalf of the SIOP-E Brain Tumour Group

    Clinical Study Open access 16 July 2016 Pages: 515 - 524

    

16. Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis

    • F. K. Holla
    • T. J. Postma
    • J. J. Heimans

    Clinical Study Open access 11 July 2016 Pages: 525 - 532

    

17. Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma

    • Anne Hertenstein
    • Thomas Hielscher
    • Antje Wick

    Clinical Study 15 July 2016 Pages: 533 - 539

    

18. Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors

    • Victoria Cheung
    • Devorah Segal
    • Matthias A. Karajannis

    Clinical Study 12 July 2016 Pages: 541 - 544

19. A cure is possible: a study of 10-year survivors of brain metastases

    • Rupesh Kotecha
    • Sally Vogel
    • Samuel T. Chao

    Clinical Study 25 July 2016 Pages: 545 - 555

    

20. Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy

    • Jacob Y. Shin
    • Aidnag Z. Diaz

    Clinical Study 11 July 2016 Pages: 557 - 565

    

21. Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients

    • Jacob Y. Shin
    • Aidnag Z. Diaz

    Clinical Study 11 July 2016 Pages: 567 - 575

    

22. Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors

    • Francesca Duraturo
    • Raffaella Liccardo
    • Paola Izzo

    Letter to the Editor 11 July 2016 Pages: 577 - 578

23. Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg)

    • Chi Tung Choy
    • Chi Hang Wong
    • Herbert Ho Fung Loong

    Letter to the Editor 18 July 2016 Pages: 579 - 581